CDMO Idifarma wins Palobiofarma contract for clinical trials
According to the agreement, contract development and manufacturing organisation (CDMO) Idifarma will prepare the compound for clinical trials from its EU good manufacturing practice (GMP) facility in Pamplona, Spain.
PBF-2897 is a novel co-crystal form of PBF-680, a candidate under investigation in Phase II clinical trials for the treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD).
According to Idifarma, the PBF-2897 project – which is due to be completed next year – is the CDMO’s seventh with Spanish firm Palobiofarma.
“Palobiofarma and Idifarma have had a strong relationship for most of the decade, successfully working together on six projects since 2012, and this latest project extends and strengthens that relationship,” said Idifarma CEO Luis Oquiñena in a statement.
Palobiofarma similarly attested to firms’ strong working relationship: ”This latest agreement with Idifarma is testament to the successful collaboration between the two companies so far.
”Without them, it would not have been possible for Palobiofarma to successfully bring seven different novel drugs into clinical development,” said Palobiofarma CEO Julio Castro.
In January this year, Idifarma announced plans to boost its spray drying services for highly potent drugs in response to growing demand. GEA’s Niro Mobile Minor spray drying technology came on line earlier at the CDMO’s Pamplona site earlier this month.
